FDA Approval of Abraxane Sets Stage for Competition Between Taxane Drugs. Abraxane a Nanotechnology Drug? Sponsor Says Yes, FDA Says.
Also in This 8-page Issue: NCI Seeks $6.17 Billion in “Bypass” Budget Request, But Faces Shortfall In Its Actual Budget.
NCI Names 15 to Director’s Consumer Liaison Group.
SAIC-Frederick Makes Awards To Proteomics Research Teams.
Latest State Cancer Statistics Released.
Smokers May Get Cessation Help From Medicare.
Funding Opportunities Listed.
Trending Stories
- As Trump’s second term nears, Republican support for NIH is at a low point
By stonewalling GOP in the House, Biden’s HHS officials eroded bipartisan support for biomedical research - Cedars-Sinai spearheads first national certification program for COE staff at cancer centers
- Menin inhibitors emerge as new treatment for advanced AML
- Trump 2016: A look back at the 45th president’s impact on oncology
- Patient navigation benefits health systems, improves care
Initial data presented at the White House come a year after CMS payment began - Larry Einhorn reflects on his pioneering work on platinum-based chemotherapy at the AACI/CCAF annual meeting